Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Monographs Take Time, Depend On Manufacturers

Executive Summary

Biologics, because of their complexity, can lengthen an already long process, USP says.

You may also be interested in...



Opioid 'Data Warehouse' Is Part Of US FDA's New Controlled Substances Program

CDER-based program lead by Marta Sokolowska will also handle benzodiazepine and stimulants activities and consult on relevant application assessments.

Oncology Center of Excellence Grows Leadership Structure, With A Vacancy Remaining

A deputy center director position remains open and four new associate director positions were added over the last year.

FDA Eyes Adverse Events For Mylan's Wixela Inhub

As patients log device complaints for Mylan’s Advair Diskus generic Wixela Inhub, the agency is assessing whether additional reminders about the products’ differences are needed.

Topics

Related Companies

UsernamePublicRestriction

Register

PS056739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel